Biogen Inc. (BIIB)
Should Value Investors Buy Biogen (BIIB) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time High
Broker upgrades focus on BIIB, TEL and ZTO as the S&P 500 and Nasdaq close at record highs on hopes U.S.-Iran peace holds.
BIIB or TECH: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Biogen Inc. (BIIB) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Biogen (BIIB) Could Beat Earnings Estimates Again
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apellis shareholders will also receive a nontransferable contingent value right (CVR) worth up to $4 per share if certain global sales milestones for SYFOVRE are achieved.
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen high-dose Spinraza approval seen supporting long-term growth
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferies say could help sustain the company's long-standing position in the rare disease market. According to the analysts, the decision was largely anticipated by investors despite earlier regulatory delays tied to manufacturing issues described as “benign.
